Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
⏸️ Investing
Would Donald Trump buy ResMed Inc. (CHESS) and Westfield Corp Ltd shares?
⏸️ Investing
Why the Nanosonics Ltd share price could head to another record high in 2017
⏸️ Investing
Earnings Wrap on Thursday: 12 shares you should have been watching
⏸️ Investing
Earnings Wrap on Tuesday: 9 shares you should have been watching
⏸️ Investing
Why these 4 shares are getting crushed today
⏸️ Investing
Results wrap: Why the Cochlear Ltd share price could head to record highs
⏸️ Investing
ASX 200 to jump on Tuesday: 8 shares you need to watch today
⏸️ Investing
Earnings season: 10 big-name shares you need to watch this week
⏸️ Investing
2 min read: 2 dynamite healthcare stocks to watch in 2017
⏸️ Investing
Why the Innate Immunotherapeutics Ltd share price is going gangbusters
⏸️ Investing
3 ASX shares with big overseas potential
⏸️ Investing
Leading fund manager is betting big on these 5 shares
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
